Novavax executives stand to collect millions even if vaccine doesn’t work

The top executives at Gaithersburg-based Novavax, one of the biotechnology companies racing to develop a coronavirus vaccine, stand to collect tens of millions of dollars in compensation even if their treatment never makes it to market. The stock options earmarked for chief executive Stanley Erck and three other company officials -- first reported by Reuters -- ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *